JP2008507326A - 医療用インプラントの生体適合性を改善するナノコーティング - Google Patents
医療用インプラントの生体適合性を改善するナノコーティング Download PDFInfo
- Publication number
- JP2008507326A JP2008507326A JP2007522487A JP2007522487A JP2008507326A JP 2008507326 A JP2008507326 A JP 2008507326A JP 2007522487 A JP2007522487 A JP 2007522487A JP 2007522487 A JP2007522487 A JP 2007522487A JP 2008507326 A JP2008507326 A JP 2008507326A
- Authority
- JP
- Japan
- Prior art keywords
- group
- nanoparticles
- combinations
- nanoparticle preparation
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 title claims abstract description 83
- 239000002103 nanocoating Substances 0.000 title description 2
- 239000002105 nanoparticle Substances 0.000 claims abstract description 141
- 239000002245 particle Substances 0.000 claims abstract description 69
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 55
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 238000000576 coating method Methods 0.000 claims abstract description 39
- 230000002265 prevention Effects 0.000 claims abstract description 35
- 239000011248 coating agent Substances 0.000 claims abstract description 34
- 238000009825 accumulation Methods 0.000 claims abstract description 33
- 239000000126 substance Substances 0.000 claims abstract description 28
- 229910052751 metal Inorganic materials 0.000 claims abstract description 26
- 239000002184 metal Substances 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 24
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 12
- 230000006432 protein unfolding Effects 0.000 claims abstract description 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 239000000017 hydrogel Substances 0.000 claims abstract description 9
- 244000005700 microbiome Species 0.000 claims abstract description 8
- 150000002739 metals Chemical class 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 6
- 239000012530 fluid Substances 0.000 claims abstract description 6
- 229910002804 graphite Inorganic materials 0.000 claims abstract description 6
- 239000010439 graphite Substances 0.000 claims abstract description 6
- 238000012544 monitoring process Methods 0.000 claims abstract description 6
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 6
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 6
- 229920002959 polymer blend Polymers 0.000 claims abstract 4
- 238000002360 preparation method Methods 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- -1 polyoxyethylene Polymers 0.000 claims description 24
- 230000036425 denaturation Effects 0.000 claims description 22
- 238000004925 denaturation Methods 0.000 claims description 22
- 238000002513 implantation Methods 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 19
- 229930195729 fatty acid Natural products 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 230000009467 reduction Effects 0.000 claims description 17
- 210000004969 inflammatory cell Anatomy 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 238000001179 sorption measurement Methods 0.000 claims description 14
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 11
- 208000007536 Thrombosis Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 230000008512 biological response Effects 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 229920006237 degradable polymer Polymers 0.000 claims description 7
- 230000009772 tissue formation Effects 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 210000000630 fibrocyte Anatomy 0.000 claims description 6
- 150000002989 phenols Chemical class 0.000 claims description 6
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 229920002799 BoPET Polymers 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000002715 modification method Methods 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 210000000515 tooth Anatomy 0.000 claims description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 5
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- 125000000837 carbohydrate group Chemical group 0.000 claims 5
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 5
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 5
- 229940051841 polyoxyethylene ether Drugs 0.000 claims 5
- 229950008882 polysorbate Drugs 0.000 claims 5
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 5
- 239000001593 sorbitan monooleate Substances 0.000 claims 5
- 229940035049 sorbitan monooleate Drugs 0.000 claims 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 5
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical class OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 claims 4
- 150000002191 fatty alcohols Chemical class 0.000 claims 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 238000007086 side reaction Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 description 40
- 108010049003 Fibrinogen Proteins 0.000 description 40
- 229940012952 fibrinogen Drugs 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 26
- 206010067484 Adverse reaction Diseases 0.000 description 15
- 208000005422 Foreign-Body reaction Diseases 0.000 description 14
- 230000006838 adverse reaction Effects 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 12
- 239000011859 microparticle Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 108010001779 Ancrod Proteins 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 229960004233 ancrod Drugs 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 229940106780 human fibrinogen Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920000867 polyelectrolyte Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010069 protein adhesion Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940071180 lauryl sulfosuccinate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/896,376 US20050084513A1 (en) | 2003-10-21 | 2004-07-21 | Nanocoating for improving biocompatibility of medical implants |
| PCT/US2005/013380 WO2006022887A1 (en) | 2004-07-21 | 2005-04-20 | Nanocoating for improving biocompatibility of medical implants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008507326A true JP2008507326A (ja) | 2008-03-13 |
| JP2008507326A5 JP2008507326A5 (enExample) | 2008-06-19 |
Family
ID=35967825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522487A Pending JP2008507326A (ja) | 2004-07-21 | 2005-04-20 | 医療用インプラントの生体適合性を改善するナノコーティング |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050084513A1 (enExample) |
| EP (1) | EP1778200A1 (enExample) |
| JP (1) | JP2008507326A (enExample) |
| CN (1) | CN101010073A (enExample) |
| CA (1) | CA2574463A1 (enExample) |
| WO (1) | WO2006022887A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005019363A1 (ja) * | 2003-08-25 | 2005-03-03 | Sakuranomiya Chemical Co., Ltd. | 金属被覆用塗料およびその塗料を塗布した金属製容器 |
| US9101279B2 (en) | 2006-02-15 | 2015-08-11 | Virtual Video Reality By Ritchey, Llc | Mobile user borne brain activity data and surrounding environment data correlation system |
| US8372126B2 (en) * | 2006-04-21 | 2013-02-12 | Warsaw Orthopedic, Inc. | Surgical fasteners with mechanical and osteogenic fixation means |
| EP2068967A2 (en) * | 2006-09-06 | 2009-06-17 | Boston Scientific Limited | Medical devices having nanostructured coating for macromolecule delivery |
| US9539062B2 (en) | 2006-10-16 | 2017-01-10 | Natural Dental Implants, Ag | Methods of designing and manufacturing customized dental prosthesis for periodontal or osseointegration and related systems |
| US7708557B2 (en) | 2006-10-16 | 2010-05-04 | Natural Dental Implants Ag | Customized dental prosthesis for periodontal- or osseointegration, and related systems and methods |
| US8602780B2 (en) * | 2006-10-16 | 2013-12-10 | Natural Dental Implants, Ag | Customized dental prosthesis for periodontal or osseointegration and related systems and methods |
| US10426578B2 (en) | 2006-10-16 | 2019-10-01 | Natural Dental Implants, Ag | Customized dental prosthesis for periodontal or osseointegration and related systems |
| US9801697B2 (en) | 2011-03-18 | 2017-10-31 | Natural Dental Implants Ag | Integrated support device for providing temporary primary stability to dental implants and prosthesis, and related methods |
| DE102007057395A1 (de) * | 2007-11-27 | 2009-05-28 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Verkapselte Mikropartikel mit einem virenhaltigen Kern und Verfahren zur Herstellung der Mikropartikel |
| US8043375B2 (en) * | 2008-03-06 | 2011-10-25 | MoiRai Orthopaedic, LLC | Cartilage implants |
| WO2009114719A2 (en) * | 2008-03-13 | 2009-09-17 | Richmond Chemical Corporation | Apparatus and method of retaining and releasing molecules from nanostructures by an external stimulus |
| US8012217B2 (en) * | 2008-07-03 | 2011-09-06 | Fellowship of Orthopaedic Researchers, LLC | Talar implants and methods of use |
| DE102008063821A1 (de) * | 2008-12-19 | 2010-06-24 | Philipps-Universität Marburg | Elektrogesponnene Polymerfasern umfassend Partikel aus Bakterien enthaltenden Hydrogelen |
| AU2010286660B2 (en) | 2009-08-25 | 2015-07-16 | Fellowship Of Orthopaedic Researchers, Inc. | Trochlear implants and methods of use |
| US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
| CN102267683A (zh) * | 2010-06-07 | 2011-12-07 | 国立清华大学 | 表面修饰的纳米粒子及其制造方法 |
| US8690956B2 (en) | 2010-08-23 | 2014-04-08 | Fellowship Of Orthopaedic Researchers, Inc. | Talar implants and methods of use |
| ES2671740T3 (es) | 2012-03-20 | 2018-06-08 | Biomet 3I, Llc | Superficie de tratamiento para una superficie de implante |
| US20150367031A1 (en) * | 2013-04-02 | 2015-12-24 | Wake Forest University Health Sciences | Methods and compositions for inhibiting fibrosis, scarring and/or fibrotic contractures |
| US11779683B2 (en) | 2019-04-08 | 2023-10-10 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| US11369473B2 (en) | 2019-04-08 | 2022-06-28 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| CN120227510A (zh) * | 2025-06-03 | 2025-07-01 | 吉林大学 | 一种抗纤维包膜的医疗植入体及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003026532A2 (en) * | 2001-09-28 | 2003-04-03 | Boston Scientific Limited | Medical devices comprising nanomaterials and therapeutic methods utilizing the same |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4406914A (en) * | 1981-08-10 | 1983-09-27 | Belden Corporation | Slotless multi-shielded cable and tape therefor |
| FR2683159B1 (fr) * | 1991-10-31 | 1994-02-25 | Coletica | Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application. |
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| JP2930421B2 (ja) * | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
| US5629021A (en) * | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| US5556380A (en) * | 1995-04-05 | 1996-09-17 | Duke University | Method for removing fibrin sheaths from catheters |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| EP0989849A2 (en) * | 1997-06-13 | 2000-04-05 | The Johns Hopkins University School Of Medicine | Therapeutic nanospheres |
| DE69921773D1 (de) * | 1998-01-16 | 2004-12-16 | Univ Johns Hopkins | Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe |
| CA2318779C (en) * | 1998-01-22 | 2009-08-25 | Luminex Corporation | Microparticles with multiple fluorescent signals |
| US6333051B1 (en) * | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
| JP2002534528A (ja) * | 1999-01-15 | 2002-10-15 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 硫酸化ホスファチジルイノシトール、それらの調製及び使用 |
| WO2000041732A1 (en) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
| WO2002067995A1 (en) * | 2001-02-26 | 2002-09-06 | Council Of Scientific And Industrial Research | Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines |
| US7128755B2 (en) * | 2001-06-01 | 2006-10-31 | Texas Stent Technologies, Inc. | Expandable biodegradable polymeric stents for combined mechanical support and pharmacological or radiation therapy |
| US20050084456A1 (en) * | 2003-10-21 | 2005-04-21 | Liping Tang | Functionalized particles |
| US20070248680A1 (en) * | 2005-02-08 | 2007-10-25 | Board Of Regents, The University Of Texas System | Particles for Inactivating Toxins |
-
2004
- 2004-07-21 US US10/896,376 patent/US20050084513A1/en not_active Abandoned
-
2005
- 2005-04-20 CN CNA2005800288126A patent/CN101010073A/zh active Pending
- 2005-04-20 CA CA002574463A patent/CA2574463A1/en not_active Abandoned
- 2005-04-20 WO PCT/US2005/013380 patent/WO2006022887A1/en not_active Ceased
- 2005-04-20 EP EP05746566A patent/EP1778200A1/en not_active Withdrawn
- 2005-04-20 JP JP2007522487A patent/JP2008507326A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003026532A2 (en) * | 2001-09-28 | 2003-04-03 | Boston Scientific Limited | Medical devices comprising nanomaterials and therapeutic methods utilizing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050084513A1 (en) | 2005-04-21 |
| EP1778200A1 (en) | 2007-05-02 |
| CN101010073A (zh) | 2007-08-01 |
| WO2006022887A1 (en) | 2006-03-02 |
| CA2574463A1 (en) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008507326A (ja) | 医療用インプラントの生体適合性を改善するナノコーティング | |
| Finbloom et al. | Bioinspired nanotopographical design of drug delivery systems | |
| Xu et al. | Modification of nanostructured materials for biomedical applications | |
| De Geest et al. | Intracellularly degradable polyelectrolyte microcapsules | |
| Shenoy et al. | Layer-by-layer engineering of biocompatible, decomposable core− shell structures | |
| Vieira et al. | Nanoparticles for bone tissue engineering | |
| Kumar et al. | Comprehensive survey on nanobiomaterials for bone tissue engineering applications | |
| Labib | Overview on zein protein: A promising pharmaceutical excipient in drug delivery systems and tissue engineering | |
| Hasirci et al. | Nanobiomaterials: a review of the existing science and technology, and new approaches | |
| Becker et al. | Layer‐by‐layer‐assembled capsules and films for therapeutic delivery | |
| Koutsopoulos | Molecular fabrications of smart nanobiomaterials and applications in personalized medicine | |
| Jia et al. | Chemical and structural engineering of gelatin-based delivery systems for therapeutic applications: a review | |
| JP2019104769A (ja) | 細胞の封入および細胞集合体のための多層ヒドロゲルカプセル | |
| Pei et al. | Materials-based drug delivery approaches: Recent advances and future perspectives | |
| Liu et al. | Preparation of silk fibroin carriers for controlled release | |
| Logothetidis | Nanomedicine and nanobiotechnology | |
| Cao et al. | Shape-dependent biodistribution of biocompatible silk microcapsules | |
| Shin et al. | Injectable macroporous ferrogel microbeads with a high structural stability for magnetically actuated drug delivery | |
| Raval et al. | Surface modifications of biomaterials and their implication on biocompatibility | |
| Athar et al. | Cellulose nanocrystals and PEO/PET hydrogel material in biotechnology and biomedicine: current status and future prospects | |
| Tabata et al. | Phagocytosis of polymeric microspheres | |
| Sousa et al. | Supramolecular dendrimer-containing layer-by-layer nanoassemblies for bioapplications: Current status and future prospects | |
| El-Sherbiny et al. | Updates on stimuli-responsive polymers: Synthesis approaches and features | |
| Ramírez-Wong et al. | Uptake of long protein-polyelectrolyte nanotubes by dendritic cells | |
| Xia et al. | Recent Advances and Challenges for Biological Materials in Micro/Nanocarrier Synthesis for Bone Infection and Tissue Engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080421 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080421 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111031 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120416 |